Modelling of the blood-brain barrier in drug discovery and development.
The market for neuropharmaceuticals is potentially one of the largest sectors of the global pharmaceutical market owing to the increase in average life expectancy and the fact that many neurological disorders have been largely refractory to pharmacotherapy. The brain is a delicate organ that can efficiently protect itself from harmful compounds and precisely regulate its microenvironment. Unfortunately, the same mechanisms can also prove to be formidable hurdles in drug development. An improved understanding of the regulatory interfaces that exist between blood and brain may provide novel and more effective strategies to treat neurological disorders.
Laboratoire de physiopathologie de la barrière hémato-encéphalique E.A.2465, IMPRT IFR-114, Université d'Artois, Faculté Jean Perrin, 62307 Lens, France. romeo.cecchelli@univ-artois.fr
Romeo
R
Cecchelli
Vincent
V
Berezowski
Stefan
S
Lundquist
Maxime
M
Culot
Mila
M
Renftel
Marie-Pierre
MP
Dehouck
Laurence
L
Fenart
D000818:Animals; D001812:Blood-Brain Barrier / Q000166:cytology / Q000378:metabolism*; D002986:Clinical Trials as Topic / Q000379:methods; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D008954:Models, Biological; D009480:Neuropharmacology / Q000379:methods; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000737:chemistry
D004364:Pharmaceutical Preparations